it wasn't clear at the time, but it sounded like it included the cells and technique, and that ALS patients could be going to Russia for treatment
price seems to rise into every update and then fall back. they really don't make it clear that the trials have only been directed at safety, that whatever actual improvement observed was not expected at such low doses
however, the fall off this time was not as great, so perhaps more people are understanding the process
those thumbs down tell you there are a lot of folks on this board that don't like to see the facts
Lincoln cannot own 10% or more of the outstanding stock,
they are already getting about 5.7 million shares free as a signing bonus, so that only leaves room for about 30 million more shares at these prices which means elite will bet less than $2.5 million
and that money, arriving at the rate of $160k per week will be be consumed repaying the loan from the ceo in july (plus 10% interest) and making overdue principal payments on the njeda loan in september
except that carter is the CFO and he did sell over 200k shares on december 9th
and, you DID post that the patents were worthless
perhaps what you are upset about is that we suggested you still believe in the billion dollar pipeline? have you changed your mind about that too?
and then there are all those shares he bought at much higher prices
couchiekoochie is just a hatin' life
could it be shorts quietly leaving, or shorts quietly adding? which would be more likely at this juncture, or neither?
how about your projected sales figure for just one of the drugs?
which one is your favorite? the one that might get us back to the low double digits for a while?
of course, a few of them have finally admitted the patents are worthless but they still believe elite has a billion dollar pipeline
if that were the case why would insiders, including the chief financial officer, sell 16 million shares in the last six months on the open market?
on the other hand, maybe the idea was that it might have caused a bigger pop, and insiders would have been able to sell ten times as many shares
these insiders have a real problem in that they own most of the stock, and nobody wants it
didn't do much for their loyal followers but most of them have become hardened masochists as a result of taking such a pounding in this stock anyway
good question. the whole market soars, the dow has doubled, and yet there are dunces here grateful to have been been losing money and volunteering to lose more
their mindless optimism is a mystery, but it appears they are simply too stupid to see reality
and mikah (hakim spelled backwards) is a company with two employees, the husband (hakim) and his wife, that has never produced or marketed anything
that's the record
she is one of the long term holders who bought cheaper shares that are green on paper, but she also has real red losses that were supposed to be on last year's taxes
from the 10-q...
Discontinued Development – Isradipine
Isradipine was one of two products in an agreement with Mikah Pharma that was intended to be transferred to Elite for manufacture. (Phendimetrazine was the second product and its launch is described above.) Preliminary production batches of Isradipine at Elite, using the equipment provided in the agreement, was not cost effective. Mikah and Elite therefore mutually agreed in an amendment to the agreement to discontinue transfer of the Isradipine.
however, while elite tries to lay the blame on the equipment provided, the agreement actually made elite responsible for supplying equipment and doing a lot more,,,
"Elite is required to perform, at its sole cost and expense, all Technology Transfer, validation and qualification services (including: equipment, methods and facility qualification), validation and stability services required by Applicable Laws to commence manufacturing Isradipine and Phendimetrazine for commercial sale by Mikah or its designees in accordance with the terms of the Isradipine/ Phendimetrazine Agreement"
its all in SEC filings available to anyone with an open mind and a smidgeon of curiosity
we have never shorted any stock because that is as anathema to the purposes for which the markets were founded as are the day trading penny stock pumpers
elite's version of a two-bead was naive from the start
a true pharmacological approach would introduce the agonist relative to the concentration of of the opioid in the blood stream